Clinical translation has yielded two FDA-approved anti-CTLA-4 monoclonal antibodies for pancreatic adenocarcinoma: ipilimumab (anti-CTLA-4 IgG1κ) and tremelimumab (anti-CTLA-4 IgG2). Here, CTLA4 is linked to pancreatic adenocarcinoma.